Cancer drugs in 16 European countries, Australia, and New Zealand: A cross-country price comparison study

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 39-47

  Vogler, Sabine ^a   Vitry, Agnes ^b   Babar, Zaheer Ud Din ^c  

^a Austrian Health Institute   (Austria)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCESS TO INFORMATION; AUSTRALIA; COMPARATIVE STUDY; DRUG COST; ECONOMIC ASPECT; ECONOMICS; EUROPE; HUMAN; NEW ZEALAND; STATISTICS AND NUMERICAL DATA;

ACCESS TO INFORMATION; ANTINEOPLASTIC AGENTS; AUSTRALIA; DRUG COSTS; ECONOMIC COMPETITION; EUROPE; HUMANS; NEW ZEALAND;

EID: 84955303274     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00449-0     Document Type: Article

References (30)

1. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
2. Cancer Care. Assuring Quality to Improve Survival 2013, OECD, OECD Health Policy Studies: OECD Publishing.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
4. Wilking N, Jönsson B A pan-European comparison regarding patient access to cancer drugs 2005, Karolinska Institutet in collaboration with Stockholm School of Economics, Stockholm.
5. Kelly RJ, Smith TJ Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014, 15:e112-e118.
6. Karikios D, Schofield D, Salkeld G, Mann K, Trotman J, Stockler M Rising cost of anticancer drugs in Australia. Intern Med J 2014, 44:458-463.
7. Luengo-Fernandez R, Leal J, Gray A, Sullivan R Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013, 14:1165-1174.
8. Brekke KR, Holmås TH, Straume OR Are pharmaceuticals still inexpensive in Norway? A comparison of prescription drug prices in ten European countries. SNF Report No. 08/10 (accessed July 5, 2015). http://brage.bibsys.no/xmlui/bitstream/handle/11250/165071/R08_10.pdf?sequence=1.
9. Kanavos PG, Vandoros S Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law 2011, 6:1-31.
10. Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices-a price comparison among 14 European countries. South Med Rev 2012, 5:34-41.
11. Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing RO, Leufkens HGM Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013, 112:209-216.
12. Vogler S, Zimmermann N, Habl C [Price analysis of 30 high-cost medicines in Austria compared to other European countries] 2015, Gesundheit Österreich GmbH, Vienna, (accessed July 5, 2015; in German). http://www.goeg.at/cxdata/media/download/berichte/15_goeg_kostenintensivearzneispezialitten_zweiteauflage.pdf.
13. Pharmaceutical pricing policies in a global market 2008, Organisation for Economic Co-operation and Development, Organisation for Economic Co-operation and Development, Paris.
14. Danzon PM, Furukawa MF International prices and availability of pharmaceuticals in 2005. Health Aff 2008, 27:221-233.
15. Kanavos P, Ferrario A, Vandoros S, Anderson GF Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff 2013, 32:753-761.
16. Vogler S, Kilpatrick K, Babar Z-U-D Analysis of medicine prices in New Zealand and 16 European countries. Value Health 2015, 18:484-492.
17. Danzon PM, Taylor E Drug pricing and value in oncology. Oncologist 2010, 15(suppl 1):24-31.
18. Babar Z-U-D Pharmaceutical prices in the 21st century 2015, Springer, Cham, Switzerland.
19. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010, 10:153.
20. Vitry A, Roughead E Managed entry agreements for pharmaceuticals in Australia. Health Policy 2014, 117:345-352.
21. Ferrario A, Kanavos P Managed entry agreements for pharmaceuticals: the European experience. EMINet (accessed July 5, 2015). http://whocc.goeg.at/Literaturliste/Dokumente/FurtherReading/ferrario_2013_mea_report_en.pdf.
22. Lu CY, Lupton C, Rakowsky S, Babar ZUD, Ross-Degnan D, Wagner A Patient access schemes in asia-pacific markets: current experience and future potential. J Pharm Policy Pract 2014, 8:1-12.
23. Williamson S Patient access schemes for high-cost cancer medicines. Lancet Oncol 2010, 11:111-112.
24. Ferrario A, Kanavos P Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med 2015, 124:39-47.
25. Robertson J, Walkom EJ, Henry DA Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev 2009, 33:192-199.
26. Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A Discounts and rebates granted to public payers for medicines in European countries. South Med Rev 2012, 5:38-46.
27. Morgan SG, Thomson PA, Daw JR, Friesen MK Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy 2013, 112:248-254.
28. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R Differences in external price referencing in Europe-A descriptive overview. Health Policy 2012, 104:50-60.
29. Vitry A, Thai L, Roughead E Pharmaceutical pricing policies in Australia. Pharmaceutical prices in the 21st century 2015, 1-24. Springer, Cham, Switzerland. Z.-U.-D. Babar (Ed.).
30. Danzon PM, Wang YR, Wang L The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Econ 2005, 14:269-292.